Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 11/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | IL6ST | P40189 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962996 | 0.91 | AGTR2 (0.35) | IDH1PPARAIL6STAGTR2FAAH | |
| SCHEMBL1155469 | 0.83 | FAAH (0.33) | IL6STAGTR2FAAHGRIN2B | |
| SCHEMBL1155471 | 0.83 | FAAH (0.33) | IL6STAGTR2FAAHGRIN2B | |
| SCHEMBL9962987 | 0.82 | IL6ST (0.44) | IDH1PPARAIL6STAGTR2FAAH | |
| SCHEMBL1155441 | 0.79 | CHRM4 (0.31) | — | |
| SCHEMBL1155442 | 0.79 | CHRM4 (0.31) | — | |
| SCHEMBL1155682 | 0.75 | PPARA (0.37) | IDH1PPARAIL6STAGTR2FAAH | |
| SCHEMBL1155686 | 0.75 | PPARA (0.37) | IDH1PPARAIL6STAGTR2FAAH | |
| SCHEMBL12833452 | 0.75 | IDH1 (0.38) | IDH1PPARAIL6STFAAHNAMPT | |
| SCHEMBL25923112 | 0.75 | PPARA (0.47) | IDH1PPARAIL6STAGTR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225886-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | IDH1 4643/4885PPARA 253/4885IL6ST 466/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | IDH1 4643/4885PPARA 253/4885IL6ST 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.